2. Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis
  4. Ifinatamab deruxtecan

Ifinatamab deruxtecan  (Synonyms: DS-7300a; MABX-9001a; I-DXd)

Cat. No.: HY-P3371 Purity: 98.98%
COA
SDS
Handling Instructions Technical Support

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

For research use only. We do not sell to patients.

Ifinatamab deruxtecan

Ifinatamab deruxtecan Chemical Structure

CAS No. : 2484870-92-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Ifinatamab deruxtecan Related Antibodies

Top Publications Citing Use of Products

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II DNA gyrase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects[1][2][3][4]

IC50 & Target[2]

Topoisomerase I

 

In Vitro

Ifinatamab deruxtecan inhibits the growth of B7-H3-expressing cancer cells in vitro, but not of B7-H3-negative cancer cells[1].
Ifinatamab deruxtecan (6 days) potently and selectively inhibits the growth of B7-H3-expressing RH-41 and MFE-280 cancer cells in vitro, with no activity against B7-H3-negative CCRF-CEM cells[2].
Ifinatamab deruxtecan (10 μg/mL; 72 hours) induces DNA damage and apoptosis in B7-H3-expressing RH-41 cancer cells in vitro[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ifinatamab deruxtecan Related Antibodies

Western Blot Analysis[2]

Cell Line: Human rhabdomyosarcoma (RH-41) cells
Concentration: 10 μg/mL
Incubation Time: 72 h
Result: Induced phosphorylation of Chk1 (a DNA damage marker) in RH-41 cells. Induced cleavage of PARP (an apoptosis marker) in RH-41 cells.
Parmacokinetics
Species Dose Route T1/2 (Elimination)
Cynomolgus Monkey[2] 0.3 mg/kg i.v. 77.76 h
Cynomolgus Monkey[2] 1 mg/kg i.v. 122.64 h
Cynomolgus Monkey[2] 3 mg/kg i.v. 189.36 h
Cynomolgus Monkey[2] 10 mg/kg i.v. 115.44 h
In Vivo

Ifinatamab deruxtecan (3-10 mg/kg; i.v.; days 0 and 14) exerts potent dose-dependent antitumor activity against rhabdomyosarcoma xenografts in mice, achieving 90% and 98% TGI at 3 mg/kg and 10 mg/kg, respectively[2].
Ifinatamab deruxtecan (0.3-3 mg/kg; i.v.; days 0 and 14) exerts potent antitumor activity against endometrial adenocarcinoma xenografts in mice, achieving 67% TGI at 0.3 mg/kg and complete tumor growth inhibition (100% TGI) at 1 mg/kg and 3 mg/kg[2].
Ifinatamab deruxtecan (1-10 mg/kg; i.v.; days 0 and 14) exerts potent dose-dependent antitumor activity against lung adenocarcinoma xenografts in mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CAnN.Cg-Foxn1nu/CrlCrlj (lung adenocarcinoma xenograft model)[2]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.v.; days 0 and 14
Result: Achieved tumor growth inhibition (TGI) of 71% at 1 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 95% at 3 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 99% at 10 mg/kg compared to vehicle control group (P < 0.001).
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Ifinatamab deruxtecan]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.29%

SDS (251 KB)

COA (231 KB) Others (331 KB) SEC-HPLC (187 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ifinatamab deruxtecan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ifinatamab deruxtecan2484870-92-8DS-7300a MABX-9001a I-DXdAntibody-Drug Conjugates (ADCs)TopoisomeraseApoptosisAntibody-Drug Conjugatescynomolgus monkeysmetastatic castration-resistant prostate cancerpatient-derived xenograft mouse modelsB7-H3-expressing solid tumorsratstumor xenograftapoptosisB7-H3 (CD276)cancer cellsDNA topoisomerase IInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ifinatamab deruxtecan
Cat. No.:
HY-P3371
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.